Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; A substudy of the PREPARE study

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 4, 2013, Pages 1659-1666

  Cotter, Aoife G ^a,b   Vrouenraets, Saskia M E ^c,d   Brady, Jennifer J ^e   Wit, Ferdinand W ^c   Fux, Christoph A ^f,g   Furrer, Hansjakob ^f   Brinkman, Kees ^h   Sabin, Caroline A ⁱ   Reiss, Peter ^c   Mallon, Patrick W G ^a,b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d SLOTERVAART HOSPITAL   (Netherlands)

^e MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^f UNIVERSITY OF BERN   (Switzerland)

^g Clinic for Infectious Diseases and Hospital Hygiene   (Switzerland)

^h University College London ^*  (Netherlands)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; OSTEOCALCIN; PARATHYROID HORMONE; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FEMALE; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TISSUE LEVEL; TREATMENT DURATION;

ADENINE; ADULT; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; COHORT STUDIES; DOWN-REGULATION; DRUG SUBSTITUTION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PARATHYROID HORMONE; VITAMIN D; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84876205918     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3686     Document Type: Article

References (19)

1. Cotter AG, Mallon PW. HIV infection and bone disease: implications for an aging population. Sex Health. 2011;8(4):493-501.
2. Bolland MJ, Grey AB, Gamble GD, Reid IR. Clinical review: low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab. 2007;92(12):4522-4528.
3. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006; 20(17):2165-2174.
4. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93(9):3499-3504.
5. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviralnaive patients: a 3-year randomized trial. JAMA.2004;292(2):191-201.
6. Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS. 2009;23(7):817-824.
7. van Vonderen MG, Lips P, van Agtmael MA, et al. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS. 2009;23(11): 1367-1376.
8. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51(8):963-972.
9. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011; 203(12):1791-1801.
10. Bolland MJ, Wang TK, Grey A, Gamble GD, Reid IR. Stable bone density in HAART-treated individuals with HIV: a meta-analysis. J Clin Endocrinol Metab. 2011;96(9):2721-2731.
11. Ofotokun I, Weitzmann N, Vunnava A, et al. HAART-induced immune reconstitution: a driving force behind bone resorption in HIV/AIDS. In: Proceedings from the 18th Conference on Retroviruses and Opportunistic Infections (CROI); February 27-March 2, 2011; Boston, MA. Paper 78.
12. + men randomized to NVP/LPV/r or AZT/3TC/LPV/r help explain limited loss of bone mineral density over the first 12 months after ART initiation. In: Proceedings from the 18th Conference on Retroviruses and Opportunistic Infections (CROI); February 27-March2, 2011; Boston, MA. Paper 833.
13. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis. 2009;49(10):1591-1601.
14. Rasmussen TA, Jensen D, Tolstrup M, et al. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS One. 2012; 7(3):e32445.
15. Haskelberg H, Hoy JF, Amin J, Ebeling PR, Emery S, Carr A; Steal Study Group. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One. 2012;7(6):e38377.
16. Vrouenraets SM, Wit FW, Garcia EF, et al. Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue. HIV Clin Trials. 2012;13(2):103-110.
17. Brandi ML. Microarchitecture, the key to bone quality. Rheumatology (Oxford). 2009;48(suppl 4):iv3-iv8.
18. Grijsen ML, Vrouenraets SM, Wit FW, et al. Low bone mineral density, regardless of HIV status, in men who have sex with men. J Infect Dis. 2013;207(3):386-391.
19. Sherr L, Lampe F, Norwood S, et al. Successive switching of antiretroviral therapy is associated with high psychological and physical burden. Int J STD AIDS. 2007;18(10):700-704.